Study Details

General Information

Forest MDD 02

A Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with Vilazodone in Patients with Major Depressive Disorder

ProtocolVLZ-MD-02
IdentifierVLZ-MD-02 Site Number 012
UIDb7b43188-b819-4596-ac1a-da01f48dd353
StatusDone - Archived
Phase4
CategoryMajor Depressive Disorder / Adult
Launch Year2012
NCT Number-
Created2012-03-02 14:39
Last Updated2012-03-02 14:39

Description

Key Elements: • To evaluate the efficacy, safety, and tolerability of vilazodone (Viibryd™) in preventing of depression relapse in patients with major depressive disorder (MDD) in comparison with placebo. Viibryd™ is already FDA approved for MDD in adults. • Patient will be randomized to 1 of 3 treatment groups (placebo, vilazodone 20 mg/day, vilazodone 40 mg/day) in a 1:1:1 ratio • Study drug administration: One tablet once-daily in the morning with food • 29 Visits/52 Weeks • Stipend: $40 per completed visit

Comment

No comment.

Target Dates

NameDateRequired
Enrollment Closed2013-11-22No
Enrollment Open2012-04-27No
First Patient First VisitNo
Site Initiation Mtg.2012-04-12No
PI Meeting Start2012-03-15No
PI Meeting End2012-03-16No
PI Meeting Arrival2012-03-14No
PI Meeting Departure2012-03-16No
Closeout Date2015-02-12No
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalMartinez, GilbertGJMartinezNo
Recruiter-No
CoordinatorPereira, CynthiaCPereiraNo
RegulatoryAguirre, SandraSAguirreNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorForest Research Institute
DivisionForest Research Institute
TeamForest Research Institute
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB RefFOR1-12-077
CRO
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorGainsboro
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?